Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia

Glycogen synthase kinase-3 (GSK3) inhibitors induce differentiation and growth inhibition of acute myeloid leukemia (AML) cells. Our pre-clinical studies showed GSK3 inhibition leads to sensitization of AML cells to tretinoin-mediated differentiation. We conducted a phase I trial of lithium, a GSK3...

Full description

Bibliographic Details
Main Authors: Masumi Ueda, Tammy Stefan, Lindsay Stetson, James J. Ignatz-Hoover, Benjamin Tomlinson, Richard J. Creger, Brenda Cooper, Hillard M. Lazarus, Marcos de Lima, David N. Wald, Paolo F. Caimi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Oncology
Subjects:
AML
differentiation
stem cells
lithium
tretinoin
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00327/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00327/full

Similar Items